Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 27, 2023 7:46pm
147 Views
Post# 35801996

RE:RE:RE:RE:ONC...The sky is NOT falling!!

RE:RE:RE:RE:ONC...The sky is NOT falling!!

Why not execute options with a .30 diferential, yet grant more at a higher price?
Assuming for a moment there is negotiations in place for a buyout.
Profiting from in place options, with that information would be a clear case of insider trading.
Meaning he has information the rest of public does not. It would be texted book illegal trading.
Other than that, no reason.
He could have taken & sold the options for a reasonable profit.
BTW, how do we know for certain he did not exercise the options.
i have not seen verification either way?
repeating myself, we will know very soon what is going on.
Two phase 3 ready trials, CAR-T , trials/ negotiations long over due. 
Recent acceptance from Pan Can of a $5 million grant.
The sky is cloudy, but not falling.
New year kick off?
changes must & will happen.
i just don't know what.
 

 

<< Previous
Bullboard Posts
Next >>